Company Profile

Profile last edited on: 7/11/16      CAGE: 5SGZ3      UEI:

Business Identifier: Ionic bio-polymers development of safe and effective treatments for drug resistant infections.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2200 Kraft Drive Suite 2475
Blacksburg, VA 24060
   (540) 443-9254
Location: Single
Congr. District: 09
County: Montgomery

Public Profile

Anchored in IP licensed from Virgina Tech, Techulon™, Inc. is addressing idevelopment, manufacture and commercialization of biopolymers and is focused to next generation of disease treatment through development of safe and effective treatments for drug resistant infections. The firm's lead candidate is targeted at MRSA. The company uses a proven method to defeat bacteria at the genomic level. Unlike current antibiotics on the market, the drugs that are derived from Techulon’s approach are potent and not susceptible to resistance.Techulon's enabling technology is a robust platform that allows for delivery of nucleic acids for a variety of therapeutic applications. Recent work on an antimicrobial platform using a novel informatics approach, the company has identified new gene targets and is developing antimicrobial therapeutics for broad applications. The firm spectializes in Synthetic polymers for life science applications and drug delivery, transfection reagents, cell therapy delivery, biodegradable transfection reagen

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 DHA $149,996
Project Title: Improving Wound Healing by Combating Multi-Drug Resistant Pathogens Using Small Molecule Antimicrobials
2014 1 Army $149,950
Project Title: Biologically-Derived Targeted Antimicrobials for Textile Applications
2013 2 DARPA $1,380,076
Project Title: Rapidly Adaptable Nanotherapeutics

Key People / Management

  Brett Malone -- President

  Joshua Bryson -- Principal Scientist

  John Engel

  Nrusingh Mohapatra